Ignite Creation Date:
2024-05-06 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04700124
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-26
First Post:
2021-01-05
Brief Title:
Perioperative Enfortumab Vedotin EV Plus Pembrolizumab MK-3475 Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer MIBC MK-3475-B15 KEYNOTE-B15 EV-304
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC